Healthcare products
Child Health
Deficiency States and Supplementation
Dermatological Health
Pain treatment
Gastrointestinal Health
Genitourinary Health
Cardiorespiratory Health
Corticotherapy
Oral-Pharyngeal Health
Fluid Therapy
CNS Treatment
Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member
Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member
We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability.
This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the goal of reducing environmental impact and accelerating solutions to address climate change.
As Silver members, we benefit from key services that strengthen our internal capabilities to manage and reduce our greenhouse gas emissions.
This membership reflects our strong commitment to sustainability, transparency, and corporate responsibility. At Laboratorios ERN, we believe that collective action and the continuous measurement of our impact are essential to contributing to a greener and more resilient future.
We will continue working with determination to reduce our emissions, promote responsible practices, and actively collaborate with initiatives that make a difference in the fight against climate change.
noticias relacionadas
Laboratorios ERN signs a collaboration agreement with Lupin Limited and launches a new medicine in Spain for the treatment of asthma and COPD
With more than 80 years of history, the laboratory founded in Barcelona continues to advance its sustainable growth strategy through alliances with leading international partners. Laboratorios ERN is taking a decisive step in strengthening its respiratory portfolio with the launch in Spain of Luforbec® (beclometasone / formoterol), 100/6, a fixed-dose combination in a pressurised metered-dose […]
Laboratorios ERN and Ercros, beneficiaries of CDTI funding for the development of the ANTISALINA project
Laboratorios ERN and Ercros are beneficiaries of public funding awarded under the National Cooperative R&D Programme of the Centre for the Development of Technology and Innovation (CDTI). Thanks to this funding, both companies are jointly advancing the ANTISALINA project, aimed at developing new innovative solutions in the field of research and experimental development. At Laboratorios […]
Launch of Intravenous Fosfomycin Commercialization in the United States
The commercialization of intravenous fosfomycin has begun in the United States. This hospital-use antibiotic is a key treatment for complicated urinary tract infections and is being introduced through a strategic agreement between LABORATORIOS ERN and the pharmaceutical company Meitheal Pharmaceuticals, a specialist in the commercialization of generic and biologic injectable products. Intravenous fosfomycin was approved […]
Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member
We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability. This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the […]
ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.
During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu. This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health, supporting projects that contribute […]